Quantitative determination of famotidine in human maternal plasma, umbilical cord plasma and urine using high-performance liquid chromatography-mass spectrometry

Xiao-Ming Wang, Erik Rytting, Doaa R. Abdelrahman, Tatiana Nanovskaya, Gary Hankins, Mahmoud Ahmed

Research output: Contribution to journalArticle

3 Scopus citations


Liquid chromatography with electrospray ionization mass spectrometry for the quantitative determination of famotidine in human urine, maternal and umbilical cord plasma was developed and validated. The plasma samples were alkalized with ammonium hydroxide and extracted twice with ethyl acetate. The extraction recovery of famotidine in maternal and umbilical cord plasma ranged from 53 to 64% and 72 to 79%, respectively. Urine samples were directly diluted with the initial mobile phase then injected into the HPLC system. Chromatographic separation of famotidine was achieved by using a Phenomenex Synergi™ Hydro-RP™ column with a gradient elution of acetonitrile and 10mm ammonium acetate aqueous solution (pH8.3, adjusted with ammonium hydroxide). Mass spectrometric detection of famotidine was set in the positive mode and used a selected ion monitoring method. Carbon-13-labeled famotidine was used as internal standard. The calibration curves were linear (r2>0.99) in the concentration ranges of 0.631-252ng/mL for umbilical and maternal plasma samples and 0.075-30.0μg/mL for urine samples. The relative deviation of method was <14% for intra- and inter-day assays, and the accuracy ranged between 93 and 110%. The matrix effect of famotidine in human urine, maternal and umbilical cord plasma was less than 17%.

Original languageEnglish (US)
Pages (from-to)866-873
Number of pages8
JournalBiomedical Chromatography
Issue number7
StatePublished - Jul 2013



  • Famotidine
  • LC-MS
  • Pregnancy
  • Umbilical cord plasma
  • Urine

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Drug Discovery
  • Pharmacology

Cite this